Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Advanced Urothelial Carcinoma
NCT04066595Phase 2Terminated
- Sponsor
- Johannes Gutenberg University Mainz
- Start
- Feb 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in urothelial carcinoma (UC), sponsored by Johannes Gutenberg University Mainz. Primary endpoint: Objective Response Rate at 6 months. Started Feb 2020; status: terminated.
02
Drugs
cabozantinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04066595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04066595.